GlassScriptPhysician profile
Bob T Souder
NPI 1316934664
$19,521.36
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,901 · 2020: $1,107 · 2021: $3,534 · 2022: $1,643 · 2023: $1,654 · 2024: $9,682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,200 · Food and Beverage: $2,183 · Travel and Lodging: $953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,200.00 |
| Food and Beverage | $2,183.14 |
| Travel and Lodging | $952.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $9,822.97 | 2021-2024 | Interstim |
| Abbvie INC. | $1,726.35 | 2019-2024 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,605.15 | 2019-2024 | Xifaxan, Trulance |
| Eli Lilly and Company | $1,600.00 | 2021 | |
| Nestle Healthcare Nutrition INC. | $644.79 | 2020-2023 | |
| Medtronic USA, INC. | $640.55 | 2019 | |
| Janssen Biotech, INC. | $636.68 | 2019-2023 | Stelara, Simponi Aria, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $599.94 | 2019-2024 | Gattex, Entyvio |
| Allergan, INC. | $366.15 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $257.62 | 2019-2023 | Linzess |
| Daiichi Sankyo INC. | $234.49 | 2019-2022 | |
| Redhill Biopharma INC. | $186.69 | 2020-2021 | |
| Ardelyx, INC. | $176.43 | 2022-2024 | Ibsrela |
| Pfizer INC. | $141.64 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $133.68 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $130.03 | 2020-2023 | Ocaliva |
| Mauna Kea Technologies, INC. | $95.31 | 2023 | |
| Qol Medical, LLC | $78.61 | 2021-2022 | |
| Braintree Laboratories, INC. | $64.20 | 2019-2024 | Suflave |
| Shire North American Group INC | $59.62 | 2019 | |
| Merck Sharp & Dohme LLC | $48.89 | 2019-2021 | |
| Celgene Corporation | $46.37 | 2021-2023 | Zeposia |
| Evoke Pharma, INC. | $41.90 | 2022-2024 | |
| Axonics, INC. | $33.37 | 2020 | |
| Genzyme Corporation | $22.08 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.72 | 2023 | Cyltezo |
| Lilly USA, LLC | $18.39 | 2023 | |
| Ucb, INC. | $18.30 | 2019 | |
| Gilead Sciences, INC. | $16.08 | 2021 | |
| Boston Scientific Corporation | $15.04 | 2023 | |
| Lucid Diagnostics INC. | $14.51 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $12.91 | 2019 | |
| Ferring Pharmaceuticals INC. | $12.90 | 2023 | Rebyota |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bob Souder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.